Cargando…

Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study

BACKGROUND: Recombinant human endostatin (rh-endostatin) is a novel antiangiogenesis drug developed in China. Previous experiments have shown that rh-endostatin can inhibit the proliferation and migration of endothelial cells and some types of tumor cells. In this study, we evaluated the efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jianghao, Yao, Qing, Li, Dong, Zhang, Juliang, Wang, Ting, Yu, Ming, Zhou, Xiaodong, Huan, Yi, Wang, Jing, Wang, Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664086/ https://www.ncbi.nlm.nih.gov/pubmed/23693018 http://dx.doi.org/10.1186/1471-2407-13-248

Ejemplares similares

Dynamic Contrast-Enhanced MR Imaging in a Phase Ⅱ Study on Neoadjuvant Chemotherapy Combining Rh-Endostatin with Docetaxel and Epirubicin for Locally Advanced Breast Cancer
por: Jia, Qianxin, et al.
Publicado: (2012)

A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
por: Yao, Xin, et al.
Publicado: (2012)

Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial
por: Yang, Houpu, et al.
Publicado: (2022)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004)

A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)
por: Kalofonos, Haralabos P., et al.
Publicado: (2004)

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, Luigi, et al.
Publicado: (2009)

Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies
por: Tuzi, Alessandro, et al.
Publicado: (2013)

Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
por: Won, Hye Sung, et al.
Publicado: (2020)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
por: Bartsch, Rupert, et al.
Publicado: (2021)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
por: Wu, Xian, et al.
Publicado: (2021)

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy
por: Zhou, Shengyu, et al.
Publicado: (2018)

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
por: Hu, Zhihuang, et al.
Publicado: (2022)

Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial
por: Pizzuti, Laura, et al.
Publicado: (2016)

The effect of ifosfamide, epirubicin, and recombinant human endostatin therapy on a cardiac angiosarcoma: A case report
por: Jiang, Lijun, et al.
Publicado: (2019)

A Phase II Trial of Neoadjuvant Chemotherapy with Genexol® (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer
por: Lee, Jinsun, et al.
Publicado: (2014)

Co-delivery of docetaxel and endostatin by a biodegradable nanoparticle for the synergistic treatment of cervical cancer
por: Qiu, Bo, et al.
Publicado: (2012)

Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients: a prospective non-randomized controlled study
por: Xu, Hairong, et al.
Publicado: (2019)

Clinical effects of cisplatin plus recombinant human endostatin (rh-endostatin) intratumoral injection on malignant central airway obstruction: a retrospective analysis of 319 cases
por: Zhou, Yunzhi, et al.
Publicado: (2021)

Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?
por: Yang, Houpu, et al.
Publicado: (2018)

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
por: Liu, Yin, et al.
Publicado: (2022)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors
por: Medioni, Jacques, et al.
Publicado: (2012)

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction
por: Moehler, Markus, et al.
Publicado: (2013)

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
por: Wang, Chengzheng, et al.
Publicado: (2023)

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
por: Gamucci, T, et al.
Publicado: (2007)

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
por: Venizelos, Andreas, et al.
Publicado: (2022)

Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial
por: Kin, Takanori, et al.
Publicado: (2020)

Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog
por: Wang, Shan, et al.
Publicado: (2016)

Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study
por: Ohnuma, Hiroyuki, et al.
Publicado: (2018)

Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients
por: Zhou, Wen-Bin, et al.
Publicado: (2010)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

A phase II trial of paclitaxel and epirubicin in advanced breast cancer
por: Rischin, D, et al.
Publicado: (2000)

Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study
por: Zhang, Jin, et al.
Publicado: (2021)

Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

A Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel and Gemcitabine in Locally Advanced Breast Cancer
por: Jeon, Ye Won, et al.
Publicado: (2017)

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
por: Li, Junjie, et al.
Publicado: (2020)

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
por: Trudeau, Maureen Elizabeth, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kh55npocirk0n0ivdq0kordqme